ACE2 and COVID-19: Our study provides a comprehensive overview of the expression of ACE2, SARS-CoV-2-priming proteases, as well as host defense and scavenging genes in the malignant lung and nearby epithelium that may constitute targets that can be repurposed for the clinical management of COVID-19 in LUAD patients.